By Ayo Onikoyi

In an unprecedented effort in the field of biomedical research, Henry Nnaemeka Ogbonna’s research work in metabolic diseases is seeking to transform the lives of individuals battling with obesity and renal cancer.

Currently pursuing a PhD at the University of Alabama at Birmingham, USA, Ogbonna’s relentless commitment to unraveling how obesity affects the effectiveness of treatment in cancer has propelled him to the forefront of scientific innovation.

His ongoing investigations into IL-1b-driven immunosuppression in obesity related renal cancer will change conventional ideas in cancer research, offering new insights into antitumor resistance. Ogbonna’s research journey, spanning from the Michael Okpara University of Agriculture, Nigeria (MOUAU) to the University of Bath, U.K., and now the University of Alabama at Birmingham, highlights his solid experience in research.

Henry Ogbonna’s research on advancing obesity and cancer research is focused on how obesity reduces the effectiveness of therapies used in managing renal cancer. His studies is seeking to identify better immunotherapies for people with obesity and renal cancer cases.

From computational methods in anti-cancer drug discovery to evaluations of herbal formulations for diabetes and inflammation, Ogbonna’s research experiences are remarkable, and has been recognized with prestigious awards such as the Blazer Graduate Research Fellowship at the University of Alabama at Birmingham.

In his words “I am committed to researching new and innovative treatments for people living with obesity and cancer”. With commitment to scientific research and community engagement over several years and countries, Ogbonna’s research journey is inspiring and transcends borders, leaving a positive influence on aspiring researchers. His journey stands as a testament to the power of innovation, and dedication in advancing scientific knowledge and societal change.